Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors’ radar screens for a reason, though there are some hidden gems that could be worth uncovering by those with a high risk tolerance.
One way to find these underappreciated stocks is by looking at companies that haven’t seen their share prices move higher lately, but have observed analysts raising earnings estimates for their stock. This trend could signal that investors haven’t quite embraced the rising estimate story yet, but that the potential for a big move higher is definitely there.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Opexa Therapeutics, Inc. ACER. This Medical - Drugs stock has actually seen estimates rise over the past month for the current fiscal year by about 26.7%. But that is not yet reflected in its price, as the stock gained only 0.16% over the same time frame.
Opexa Therapeutics, Inc. Price and Consensus
Opexa Therapeutics, Inc. Price and Consensus | Opexa Therapeutics, Inc. Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 38.5%, which should ultimately translate into price appreciation.
And if this isn’t enough, ACER currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Opexa Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for ACER and that now might be an interesting buying opportunity.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Opexa Therapeutics, Inc. (ACER) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research